April 30, 2024
Women who are considered to be at average risk for breast cancer should have mammograms every other year starting at age 40 years until age 74, […]
April 30, 2024
Adjuvant therapy with aspirin offers no protection against recurrence or survival benefit in patients with high-risk nonmetastatic breast cancer, the results of a new phase 3 […]
April 30, 2024
Stereotactic radiosurgery appears to be feasible, safe, and effective for patients with 15 or more brain metastases and may be a viable alternative to whole brain […]
April 29, 2024
TOPLINE: Immune checkpoint inhibitors (ICIs) are now widely used immunotherapies for many cancers, but their use in pregnancy is discouraged because of the lack of safety […]
April 26, 2024
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia […]
April 26, 2024
At its April 2024 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) made recommendations for Fruzaqla, Truqap, and Eribulin Baxter […]
April 26, 2024
TOPLINE: In patients with non–small cell lung cancer (NSCLC) who have metastases to the brain only, definitive treatment to the primary site improved overall survival outcomes […]
April 25, 2024
Overall, cancer mortality in the United States has declined over the past few decades. But there are some exceptions. Deaths from endometrial cancer, for instance, have […]
April 25, 2024
For patients with relapsed/refractory follicular lymphoma (R/R FL), chimeric antigen responder (CAR) T-cell therapy offers the best chance of survival, despite its high rate of serious […]